- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Delhi HC asks CDSCO, Cipla to reply on PIL seeking to allow all Remdesivir makers to sell in domestic market
The petition has also said that huge stocks of the medicine are lying at the ports for being exported and the same can be sold in the domestic market.
New Delhi: The Delhi High Court Monday asked the Centre and various pharma majors to respond to a PIL seeking that all drug firms making Remdesivir, used in COVID-19 treatment, be allowed to sell it in the domestic market.
A bench of Chief Justice D N Patel and Justice Jasmeet Singh issued notice to the Health Ministry, Central Drugs Standard Control Organisation, Director General of Foreign Trade and various pharma companies, like Cipla, Zydus and Cadila, seeking their stand on the plea which claims only a handful of such firms are allowed to sell the medicine in the domestic market.
The remaining companies were involved in manufacturing the drug for export, petitioner Dincur Bajaj said, adding that since export of Remdesivir has been banned by the Centre, the companies which were producing it for export be permitted to manufacture and sell it in the domestic market.
Bajaj, who is a lawyer and the Joint Secretary of the Delhi High Court Bar Association, has claimed that there are more than 25 companies in India which manufacture the medicine, but only six to eight of them are permitted to sell it in the domestic market and the rest were producing it for exports alone.
The plea, filed through advocate Amit Saxena and Imran Ali, has said, "It is pertinent to mention that the scarcity of Remdesivir is causing its extensive black-marketing and the black marketers are charging prices up to Rs 1,00,000 per vial, due to its non-availability.
During the hearing, the central government said that the Supreme Court in its order dated April 30 has dealt with the issue of sale of essential medicines and has issued directions to the Centre in this regard.
Saxena, opposed the contention, saying the apex court's order primarily deals with sale of vaccines.
The petition has also said that huge stocks of the medicine are lying at the ports for being exported and the same can be sold in the domestic market.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Next Story